查詢結果分析
相關文獻
- 比較碳青黴烯酶的有無對具碳青黴烯類抗藥性的克雷伯氏肺炎桿菌菌血症患者的預後影響
- 北部某區域醫院克雷伯氏肺炎桿菌碳青黴烯酶之分子流行病學分析
- 內因性克雷伯氏肺炎桿菌眼內炎之病例討論
- 化膿性肝膿瘍病例介紹及用藥評估
- Prostatic Abscess in Southern Taiwan: Another Invasive Infection Caused Predominantly by Klebsiella Pneumoniae
- 化膿性肝膿瘍的現況
- 以多面向介入策略消除院內對Carbapenem抗藥之克雷伯氏肺炎桿菌群突發之經驗探討
- 碳青黴烯(Carbapenem)抗藥性腸道菌:抗藥機轉與感染控制
- Fatal Bacteremic Pneumonia due to Klebsiella pneumoniae after Near-Drowning
- 又一個新型超級病菌出現
頁籤選單縮合
| 題 名 | 比較碳青黴烯酶的有無對具碳青黴烯類抗藥性的克雷伯氏肺炎桿菌菌血症患者的預後影響=Comparing the Outcomes of Patients with Carbapenemase-producing and Non-carbapenemase-producing Carbapenem-resistant Klebsiella pneumoniae Bacteremia |
|---|---|
| 作 者 | 周育德; 金琬; 劉思妤; 莊茜; 林邑璁; | 書刊名 | 感染控制雜誌 |
| 卷 期 | 35:5 2025.10[民114.10] |
| 頁 次 | 頁284-298 |
| 分類號 | 415.2749 |
| 關鍵詞 | 抗碳青黴烯類腸桿菌; 碳青黴烯酶; 克雷伯氏肺炎桿菌; Carbapenem-resistant Enterobacterales; Carbapenemase; Klebsiella pneumoniae; |
| 語 文 | 中文(Chinese) |
| DOI | 10.6526/ICJ.202510_35(5).0002 |
| 中文摘要 | 具碳青黴烯類抗藥性的腸桿菌根據其抗藥機轉可分為具碳青黴烯酶和不具 碳青黴烯酶,而碳青黴烯酶對病人預後的影響仍不明確,因此我們比較產碳青黴 烯酶抗碳青黴烯類克雷伯氏肺炎桿菌 (carbapenemase-producing carbapenemresistant Klebsiella pneumoniae, CP-CRKP) 和非產碳青黴烯酶抗碳青黴烯類克雷 伯氏肺炎桿菌 (non-carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae, non-CP-CRKP) 之菌血症病人的死亡率。 我們回溯性研究收集 2012 年 8 月到 2019 年 12 月期間,因感染抗碳青黴烯 類克雷伯氏肺炎桿菌 (carbapenem-resistant Klebsiella pneumoniae, CRKP) 菌血 症而於臺北榮民總醫院住院的病人,使用聚合酶連鎖反應偵測菌血症分離株的碳 青黴烯酶,再利用 Cox 迴歸分析找出與 14 天死亡率相關的風險因子。 此研究期間收集了 165 位 CRKP 菌血症病人,包括 115 位 (69.7%) 感染 CP-CRKP 和 50 位 (30.3%) 感染 non-CP-CRKP,整體 14 天死亡率為 41.8%, 前者的 14 天死亡率比後者顯著較高 (47.0% vs 30.0%, p=0.042),多變項分析 顯示帶有碳青黴烯酶並非 14 天死亡率的獨立因子,血液腫瘤之共病症(風險比 =2.678,95% 信賴區間 =1.457-4.922,p=0.002)、Pitt Bacteremia score(風 險比 =1.179,95% 信賴區間 =1.017-1.367,p=0.029)和敗血性休克(風險比 =2.223,95% 信賴區間 =1.016-4.865,p=0.046)為顯著的危險因子。 由此發現感染 CRKP 菌血症有著很高的死亡率,但是否帶有碳青黴烯酶與 14 天死亡率無顯著相關。 |
| 英文摘要 | Carbapenem-resistant Enterobacterales (CRE) develop resistance through two main mechanisms: carbapenemase-producing (CP) and non-carbapenemaseproducing (non-CP). However, it remains unclear whether carbapenemase production affects patient mortality. Therefore, this study aimed to compare the mortality of patients with carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae (CP-CPKP) and non-carbapenemase-producing carbapenemresistant Klebsiella pneumoniae (non-CP-CRKP) bacteremia. We conducted an observational study including patients with carbapenemresistant Klebsiella pneumoniae (CRKP) bacteremia hospitalized at Taipei Veterans General Hospital from August 1, 2012, to December 31, 2019. The primary outcome was 14- day mortality. Polymerase chain reaction was performed on all isolates to identify carbapenemase-encoding genes. The relationships between clinical variables and outcomes were analyzed using Cox regression models. A total of 165 patients with CRKP bacteremia were retrospectively analyzed, including 115 with CP-CRKP and 50 with non-CP-CRKP bacteremia. The overall 14-day mortality rate was 41.8%. Patients with CP-CRKP bacteremia had a higher 14-day mortality rate than those with non-CP-CRKP (47.0% vs. 30.0%, p = 0.042). Multivariable analysis revealed that carbapenemase production was not independently associated with 14- day mortality. Independent risk factors for 14-day mortality included hematologic malignancy (hazard ratio, 2.678; 95% confidence interval, 1.457–4.922; p = 0.002), high Pitt bacteremia score (hazard ratio, 1.179; 95% confidence interval, 1.017– 1.367; p = 0.029), and septic shock (hazard ratio, 2.223; 95% confidence interval, 1.016–4.865; p = 0.046). Our findings suggest that patients with CRKP bacteremia have high 14-day mortality; however, carbapenemase production was not associated with 14-day mortality in CRKP bacteremia. |
本系統中英文摘要資訊取自各篇刊載內容。